<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175655</url>
  </required_header>
  <id_info>
    <org_study_id>EC 28105</org_study_id>
    <nct_id>NCT01175655</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation</brief_title>
  <acronym>MSC in OB</acronym>
  <official_title>A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Prince Charles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cell &amp; Tissue Therapies Western Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Prince Charles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to establish the safety of infusions of Mesenchymal Stromal
      Cells (MSC) from related or unrelated Human Leukocyte Antigen (HLA) identical or HLA
      mismatched donors in the management of bronchiolitis obliterans syndrome after lung
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the safety of infusions of MSC from related or unrelated HLA identical or HLA mismatched donors in the management of bronchiolitis obliterans syndrome after lung transplantation.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To document changes in lung function and 6 minute walk distance (6MWD) following infusion of MSC</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To document survival post MSC infusion</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MSC</intervention_name>
    <description>mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks</description>
    <arm_group_label>MSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with single, bilateral or heart-lung allografts

          2. Patients with bronchiolitis obliterans syndrome (BOS) grades 2 &amp; 3 (defined and graded
             according to international criteria (Appendix 1)), with evidence of deterioration in
             allograft function (i.e. deteriorating FEV1 or worsening BOS grade) within the last 12
             months.

          3. Patients with BOS grade 1 and evidence of deterioration in allograft function (i.e.
             deteriorating FEV1 or worsening BOS grade) within the last 12 months and at least one
             of the following additional risk factors for subsequent death:

               -  Single lung transplant

               -  Rapid deterioration (&gt;20% fall in FEV1 in the previous 12 months)

               -  A pre-transplant diagnosis of usual interstitial pneumonia (pulmonary fibrosis)
                  or pulmonary hypertension

        Exclusion Criteria:

          1. Patients with active infection, acute allograft rejection, or airway anastomotic
             complications

          2. Patients with &gt; 3 infective exacerbations of BOS in the last 12 months

          3. Patients with a history of cytomegalovirus (CMV) pneumonitis

          4. Patients with poor performance status and/or not expected to survive 3 months

          5. Patients who are pregnant or breastfeeding

          6. Patients with an allergy to beef products.

          7. Any condition that in the opinion of the Investigator may interfere with the safety of
             the patient, his / her completion of required follow-up visits or evaluation of the
             study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Chambers, A/Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Prince Charles Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TPCH</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RPH</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Prince Charles Hospital</investigator_affiliation>
    <investigator_full_name>Daniel Chambers</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal stromal cells</keyword>
  <keyword>Bronchiolitis obliterans</keyword>
  <keyword>Lung transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

